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Background: Influenza is rarely confirmed with laboratory testing and accurate assessment of the overall burden of
influenza is difficult. We used statistical modelling methods to generate updated, granular estimates of the number/rate
of influenza-attributable hospitalisations and deaths in the United Kingdom. Such data are needed on a continuing basis
to inform on cost-benefit analyses of treatment interventions, including vaccination.
Methods: Weekly age specific data on hospital admissions (1997–2009) and on deaths (1997–2009) were obtained from
national databases. Virology reports (1996–2009) of influenza and respiratory syncytial virus detections were provided by
Public Health England. We used an expanded set of ICD-codes to estimate the burden of illness attributable to influenza
which we refer to as ‘respiratory disease broadly defined’. These codes were chosen to optimise the balance between
sensitivity and specificity. A multiple linear regression model controlled for respiratory syncytial virus circulation, with
stratification by age and the presence of comorbid risk status (conditions associated with severe influenza outcomes).
Results: In the United Kingdom there were 28,516 hospitalisations and 7163 deaths estimated to be attributable to
influenza respiratory disease in a mean season, with marked variability between seasons. The highest incidence rates of
influenza-attributable hospitalisations and deaths were observed in adults aged 75+ years (252/100,000 and 131/100,000
population, respectively). Influenza B hospitalisations were highest among 5–17 year olds (12/100,000 population). Of all
estimated influenza respiratory deaths in 75+ year olds, 50 % occurred out of hospital, and 25 % in 50–64 year
olds. Rates of hospitalisations and death due to influenza-attributable respiratory disease were increased in adults
identified as at-risk.
Conclusions: Our study points to a substantial but highly variable seasonal influenza burden in all age groups,
particularly affecting 75+ year olds. Effective influenza prevention or early intervention with anti-viral treatment in
this age group may substantially impact the disease burden and associated healthcare costs. The high burden of
influenza B hospitalisation among 5–17 year olds supports current United Kingdom vaccine policy to extend quadrivalent
seasonal influenza vaccination to this age group.
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Annual influenza epidemics results in illness among in-
dividuals in all age groups, and large numbers of hospital
admissions and deaths [1–3]. Genetic drift of influenza
viruses causes frequent changes in the circulating virus
strains and limited continuing immunity from 1 year to
the next. The circulating virus subtypes in any one sea-
son, the relative impact on different age groups, and the
timing of epidemic onset are not readily predictable [4].
The World Health Organization makes recommendations
on the virus strains to be used in influenza vaccines for the
forthcoming season, but mismatches between the chosen
strain and the eventual circulating strain may occur.
Prior to 2012, influenza vaccination in the United
Kingdom (UK) was recommended for all individuals aged
65+ years, those with comorbid conditions which defined
them as at risk of complications of influenza, and all preg-
nant women. In 2012, the Joint Committee on Vaccination
and Immunisation recommended that influenza vaccin-
ation be extended to include all children between 2 and
17 years of age, with phased introduction of the programme
beginning in 2013 [5].
Between 1966 and 2006 the incidence of influenza-like
illness in England and Wales has declined gradually,
albeit with peaks during severe epidemics in some years
[6]. The cause of the reduction in incidence is not ex-
plained, but similar reductions in incidence have been
observed for other respiratory diagnoses in the UK and
the Netherlands [7, 8]. These fluctuations emphasise the
need for regular re-assessment of the impact of influenza
and other viruses using contemporary data. Assessment
of the burden of illness due to influenza is not straight-
forward because not all sufferers consult a doctor, many
other respiratory viruses produce similar symptoms and
the diagnosis is rarely confirmed by laboratory testing.
Moreover, much of the burden results from complica-
tions which are not necessarily directly attributed to in-
fluenza as the underlying cause.
Statistical modelling techniques are used to explore
the total burden of influenza. A widely practiced method
measures excess influenza-related health outcomes during
the winter over a seasonally variable baseline [9]. However,
limited data about other respiratory viruses (including
some not yet identified) may lead to overestimation of the
influenza burden. Techniques using regression modelling
to assign a proportion of an outcome to influenza address
these difficulties [2, 10]. Most recently, these methods
have been adapted to allow estimation of the proportion
of an outcome attributable to a particular pathogen whilst
controlling for other pathogens associated with the out-
come [11].
We used regression modelling methods to estimate
mortality and hospitalisations attributable to influenza in
the UK according to age, influenza type and subtype,and considering known comorbid risk factors for severe
influenza. We controlled for respiratory syncytial virus
(RSV), which has similar winter seasonality to influenza.
The results comprehensively describe the burden of hos-
pitalisations and deaths over 12 and 13 seasons, respect-
ively, using several influenza-related outcome definitions
of varying sensitivity and specificity. We also report on a
new outcome, ‘respiratory disease broadly defined’, that
combined all respiratory diagnoses with sepsis, unspeci-
fied viral infections and selected presenting symptom.
This definition was designed to have high sensitivity
while maintaining reasonable specificity.
Methods
Study design
We extracted data from national databases in a time
series model to estimate the burden of influenza disease
in the UK in each season (July in the index year through
June in the following year) between 1996 and 2009
(www.clinicaltrials.gov NCT01520935). Seasons after July
2009 were disturbed by the pandemic experience in the
summer of 2009 and were not included to allow us to es-
tablish the normal or average seasonal burden of influenza.
The inclusion criterion was registration with a poten-
tially influenza-related event (respiratory and all other
outcomes) in the Hospital Episode Statistics (HES) or
Office of National Statistics (ONS) databases. The proto-
col was approved by the Independent Scientific Advisory
Committee of the Clinical Practice Research Datalink
(CPRD). Informed consent was not required.
Data sources
Weekly virological surveillance data for influenza A, in-
fluenza B and RSV were obtained from the UK national
surveillance system at Public Health England (PHE).
Influenza and RSV reports were based on virus swab-
positive nose/throat swabs or nasopharyngeal aspirates
notified to PHE. For influenza, strain type A or B was
specified on reports but subtype was not always pro-
vided, so viruses were classified as A or B.
Data from 1997 to 2009 (data could not be extracted
before April 1997), were extracted from the HES database
(described in Additional file 1) which captures records
from almost all patients admitted to National Health
Service non-psychiatric hospitals in England. Records
for each influenza-related emergency admission were
extracted using International Classification of Diseases
(ICD) codes version 10.
All deaths in England and Wales are registered with
the ONS (Additional file 1) and coded using ICD classifi-
cation of cause (ICD-9 prior to 2002, ICD-10 thereafter).
Data were extracted from the ONS database from 1996 to
2009. Patients who died in hospital were identified using
HES data. As recommended by ONS, we adjusted for this
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average baseline rates of incidence for the respiratory out-
comes for which sharp differences (departing from trend
estimates) were observed between 2000 and 2001 to the
1996–2000 outcome counts (e.g., 1.22, 1.69 and 2.09 re-
spectively for the primary outcome categories ‘all respira-
tory diagnoses’, ‘pneumonia and influenza’ and ‘bronchitis
and bronchiolitis’). These adjustments produced time
series that were not substantially different before and after
the version change.
Outcome definitions
Outcome definitions were designed to span a range of
sensitivity and specificity (Additional file 1: Table S1).
We developed an outcome category ‘respiratory disease
(broadly defined)’ that included codes for diseases of the
respiratory system (ICD-10 ‘J’ codes), cough and abnor-
malities of breathing, non-specific viral infections, and
sepsis. A negative control outcome (accidents) was also
examined. In this report, unless otherwise noted, all out-
comes are based either on the primary diagnosis (hospi-
talisations and in-hospital deaths) or underlying cause
(ONS deaths).
Comorbid risk status
Each HES admission record and ONS record was reviewed
for ICD codes indicative of co-morbidity which would pri-
oritise the patient to receive influenza vaccination [12]:
chronic obstructive pulmonary disease, cardiovascular
disorders, kidney disorders, diabetes, immunosuppres-
sion, liver disorders, stroke, central nervous system dis-
orders (Additional file 1: Table S2). Comorbid risk
status could only be based on what was listed on the
admission or death record under study, as patients
could not be linked to their other health encounters.
Denominators
The population of the UK (2012) is approximately 63.7
million, of which 53.5 million reside in England, 5.3
million in Scotland, 3.1 million in Wales and 1.8 million
in Northern Ireland. We used the population distribu-
tion of age-specific risk derived from a companion study
set in the CPRD population and extrapolated to the en-
tire UK population in 2001 (ONS, [13]) as denominators
for HES and ONS risk-stratified estimates. The companion
study established excellent agreement between CPRD and
independent data sources for the UK with respect to the
population age structure, the prevalence of various risk fac-
tors, and influenza vaccination coverage [14].
Statistical methods
Statistical analyses were performed using SAS 9.2. Weekly
time-series of the number of specimens positive forinfluenza A, influenza B and RSV were generated using
PHE virology surveillance data. Weekly time-series for
influenza-related health outcomes (Additional file 1: Table
S1) were generated from HES and ONS data for age
groups <5, 5–17, 18–49, 50–64 (and 65–74 and 75+ ex-
amined separately) and low/high comorbid risk group. A
multiple linear regression model was applied to each age
group to associate hospitalisations or deaths to influenza
A or B, while controlling for RSV and unspecified seasonal
factors. Major changes in virus detection methodology
were undertaken by PHE in 2001; thus, to avoid bias the
model separated the periods before and after this date.
β0+ βs1t + βs2t
2+ βs3t
3+ βs4sin(2πt/52.18) + βs5cos(2πt/
52.18) + βp1aInfluenza A(pre-July 2001) + βp1bInfluenza
A(post-July 2001) + βp2aInfluenza B(pre-July 2001) + βp2b
Influenza B(post-July 2001) + βp3aRSV(pre-July 2001) +
βp3aRSV(post-July 2001)where t = time in days since 1 July
1995; Influenza A, Influenza B and RSV are observed
counts of positive tests from the PHE LabBase dataset.
The influenza burden was derived from parameters βp3a
through βp2b.
Pathogen predictor variables were transformed into
proportions by dividing weekly positive tests by the total
number of positives for the season (July to June). Both
predictors produced models with similar explanatory
power. Outcome and pathogen series were tri-mean-
smoothed. The weekly attribution to each virus was
computed as the product of the observed value of the
explanatory variable (i.e., number of positive virology
samples) and the corresponding regression coefficient
(βp1a through βp2b), and the weekly estimates summed to
produce the seasonal estimates. Confidence intervals
were based on the standard error of the pathogen par-
ameter estimate. Specifically, we first took each weekly
point estimate, multiplied by the regression coefficient,
and aggregated the weekly estimates over the entire sea-
son. We then repeated the procedure using the lower
and upper 95 % estimates for the regression parameter
to obtain the seasonal upper and lower confidence inter-
vals. The variability of annual all-age estimates was
assessed using standard deviations. Results were expressed
as numbers of hospitalisations or deaths, and as the mean
seasonal (from September to mid-May) rates of hospitali-
sations or deaths per 100,000 population.
We considered the possibility that observed prevalence
of pathogens could have its effect on outcomes at a dis-
tance of one or more weeks. Therefore, we investigated
the effects of lagging the virology data, especially those
for RSV because these samples are almost exclusively
derived from children <5 years [10]. In the absence of
hard data regarding RSV infection in the elderly, we
suggest that the efficacy of the lagged variable in the re-
gression models reflects an actual sequential pattern of
infection across age groups. The best model fit was
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for HES and ONS outcomes in individuals >18 years of
age. Lagging the influenza series did not result in con-
sistently higher or lower influenza burden attributions.
The final model was optimised by excluding summer
months, smoothing the time series, and consideration of
two periods for two pathogen time series (pre- and
post-July 2001 season periods corresponding to major
changes in virus detection methodology undertaken by
PHE at that time).
Results
Model fit
The goodness of fit was assessed using adjusted R2
(co-efficient of determination). Fit was very good in
most strata. For hospitalisations the adjusted R2 was
greater than 0.87 for the respiratory outcome for all
age strata except 5–17 years, which had an R2 of 0.51;
for deaths, the adjusted R2 was above 0.81 for the two
oldest age groups, but lower for the younger age groups in
which death was a relatively rare outcome. Moreover, we
found a substantial “lift” in the adjusted R2 value when
introducing the virology terms into the base secular
model. We did not adjust the model form (by including
or excluding terms) individually for each outcome, age,
and risk stratum, but applied the given form across all
strata. The all-age analyses of influenza-attributable ad-
missions for the control outcome (accidents), disclosed
no excesses (Table 1).
Hospitalisations
As expected, there was marked variability in influenza-




Respiratory Broadly defined 27,237 (17,895)
Respiratory 25,725 (16,706)




Accidents (control outcome) 0 (595)
Mortality: Underlying
Respiratory Broadly defined 6561 (5501)
Respiratory 6478 (5419)
Pneumonia & influenza 3155 (2787)
Cardiorespiratory 11,661 (10,168)
N Number of episodes, SD standard deviation, Rate per 100,000 population
Hospitalisations from HES 1997–2009, deaths from ONS, 1996–2009(broadly defined) from season to season (Fig. 1). In a mean
season there were 28,516 hospitalisations for respira-
tory disease attributable to influenza, corresponding to
an overall rate of 49/100,000 population (Table 1). Of
these, 27,237 hospitalisations (range across seasons 6757
to 62,427) were attributable to influenza A, and 1279
(range across seasons 0 to 5708) to influenza B, corre-
sponding to an overall rate of 46/100,000 and 2/100,000
population, respectively (Table 1). The all age seasonal es-
timates of respiratory (primary diagnosis) and cardiorespi-
ratory hospitalisations (primary diagnosis) attributable to
influenza were slightly lower than those for respiratory
disease (broadly defined).
The highest mean seasonal rates estimate for influenza-
attributable hospitalisations were observed in adults
75+ years (Table 2). Our estimate of the influenza-
attributable respiratory (broadly defined) hospitalisa-
tion rate in this age group was 2-fold higher than that
of people 65–74 years, and accounted for 36 % of all
hospitalisations.
The mean estimated seasonal hospitalisation rate for
respiratory disease attributable to influenza A exceeded
those attributable to influenza B for all age groups,
except for those aged 5–17 years (Table 2). Influenza B-
attributable respiratory admissions exceeded those at-
tributable to influenza A in 5–17 year olds in five of the
seasons studied, and in 18–49 year olds in two of the
seasons studied (data not shown).
Investigation of non-respiratory diagnoses (cardiovas-
cular disease, central nervous system, diabetes and renal
disease) showed a tenuous association between influenza
and these outcomes, predominantly in the older age
groups (Additional file 1: Table S3).r 100,000 population, all ages) attributable to influenza
Influenza B
Rate (SD) N (SD) Rate (SD)
46 (30) 1279 (1914) 2 (3)
44 (28) 703 (2060) 1 (4)
12 (7) 236 (1066) 0 (2)
43 (29) 57 (2414) 0 (4)
48 (33) 921 (3257) 2 (6)
0 (1) 0 (935) 0 (2)
11 (9) 602 (681) 1 (1)
11 (9) 592 (679) 1 (1)
5 (5) 373 (442) 1 (1)
20 (17) 990 (1135) 2 (2)
Fig. 1 Seasonal hospitalisation and death rates for respiratory
disease* attributable to influenza A, B and RSV. Footnote: vertical
bars = 95 % confidence intervals, RSV respiratory syncytial virus
*broadly defined
Table 2 Mean seasonal hospitalisations for respiratory diseasea
attributable to influenza by age and risk statusb
Influenza A Influenza B
Age Risk N (SD) Rate (SD) N (SD) Rate (SD)
0–4 All 3247 93 0 0
Low 3866 111 0 0
High 0 0 0 0
5–17 All 796 8 1173 12
Low 1009 10 1295 13
High 0 0 144 1
18–49 All 3273 13 652 2
Low 1754 7 549 2
High 15,509 59 1501 6
50–64 All 4005 39 51 0
Low 1454 14 68 1
High 12,793 124 0 0
65–74 All 5019 101 0 0
Low 1743 35 0 0
High 9828 199 0 0
75+ All 10,195 252 0 0
Low 6625 164 0 0
High 13,181 326 0 0
All agesc All 27,237 (17,895) 46 (30) 1279 (1914) 2 (3)
Low 14,238 (9261) 24 (16) 1836 (1803) 3 (3)
High 84,142 (61,066) 143 (104) 0 (7759) 0 (13)
N Number of episodes, SD standard deviation, Rate per 100,000 population,
Hospitalisations from HES 1997–2009
abroadly defined
brisk group defined according the chronic conditions indicative of risk for
severe influenza as per UK recommendations for influenza vaccination. These
include chronic obstructive respiratory disease; cardiovascular, central nervous
system, renal and liver disorders; diabetes; immunosuppressive conditions
or stroke
cthe attributions for each age group are not equal to the sum of the attributions
(all ages) due to separately run models
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Considering mean seasonal influenza-attributed HES
deaths as a proportion of all influenza-attributable ONS
deaths, 50 % of all respiratory (broadly defined) deaths
attributed to influenza occurred in hospital (Table 3).
The proportion of all influenza respiratory deaths that
occurred in hospital was higher in the 50–64 (75 %)
and 65–74 (65 %) year age groups, than in those 75+ years
(50 %). The overall mortality rate of influenza-attributable
hospitalizations (HES deaths divided by HES hospitalisa-
tions) was 12 % for hospitalised patients with a respiratory
(broadly defined) diagnosis, and was higher in the elderly
(26 % in those aged 75+ years). Over time, there was a
trend toward more influenza attributable deaths occurring
in hospital (data not shown).Mortality
In a mean season there were an estimated 7163 respira-
tory (broadly defined) deaths attributable to influenza,
with a mean seasonal mortality rate of 12/100,000 popula-
tion (Table 1). As for hospitalisations, there was marked
inter-season variability in influenza-attributable mortality
rates due to respiratory disease (Fig. 1). Few influenza-
attributable respiratory deaths were reported in children
and adolescents <18 years of age (19/7163) (Table 4). Most
deaths (74 %, 5288/7163) attributable to influenza re-
spiratory disease were in adults aged 75+ years. The
mean seasonal mortality rate attributable to influenza
in those aged 75+ years was 6.5-fold higher than in those
aged 65–74 years for respiratory disease (broadly defined).
The all age seasonal estimate for deaths due to respira-
tory disease (broadly defined) attributable to influenza
was slightly larger than that of respiratory deaths, but
Table 3 Hospitalisation and mortality rates due to influenza-attributable respiratory diseasea by place of death and age-group
Age group (years) Hospitalisations (HES) Deaths (ONS) Inpatient deaths
(HES deaths)
% of hospitalised patients
who died in hospitalb
% of ONS-reported deaths that
occurred in hospitalc
0–4 93 0 0 – –
5–17 20 0 0 – –
18–49 15 0 0 – –
50–64 39 4 3 8 % 75 %
65–74 101 20 13 13 % 65 %
75+ 252 131 65 26 % 50 %
All ages 49 12 6 12 % 50 %
Hospitalisations according to primary diagnosis, deaths according to underlying diagnosis
abroadly defined
bcalculated from mean seasonal attributed HES deaths (rate /100,000) divided by mean seasonal attributed hospitalisations (rate /100,000)
ccalculated from mean seasonal attributed HES deaths (rate /100,000) divided by mean seasonal attributed ONS deaths (rate /100,000)
Table 4 Mean seasonal mortality for respiratory diseasea
attributable to influenza according to age and risk statusb
Influenza A Influenza B
Age Risk N (SD) Rate (SD) N (SD) Rate (SD)
0–4 All 12 0 1 0
Low 13 0 2 0
High 3 0 0 0
5–17 All 4 0 2 0
Low 2 0 0 0
High 16 0 19 0
18–49 All 84 0 13 0
Low 61 0 9 0
High 278 1 45 0
50–64 All 402 4 27 0
Low 145 1 16 0
High 1316 13 71 1
65–74 All 955 19 27 1
Low 367 7 0 0
High 1875 38 79 2
75+ All 4776 118 512 13
Low 5042 125 671 17
High 4627 114 375 9
All agesc All 6561 (5501) 11 (9) 602 (681) 1 (1)
Low 3672 (3107) 6 (5) 436 (501) 1 (1)
High 19762 (17261) 34 (29) 1395 (1569) 2 (3)
N Number of episodes, SD standard deviation, Rate per 100,000 population,
Deaths from ONS 1996–2009
abroadly defined
bRisk group defined according the chronic conditions indicative of risk for
severe influenza as per UK recommendations for influenza vaccination. These
include chronic obstructive respiratory disease; cardiovascular, central nervous
system, renal and liver disorders; diabetes; immunosuppressive conditions
or stroke
cthe attributions for each age group are not equal to the sum of the attributions
(all ages) due to separately run models
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diorespiratory disease (Table 1). Most excess influenza-
attributable cardiovascular deaths were in older adults
(Additional file 1: Table S4). There were more influenza-
attributable respiratory (broadly defined), pneumonia
and influenza and cardiorespiratory deaths (all ages) cap-
tured under the any mention criterion versus the under-
lying cause (Additional file 1: Table S4).
Discussion
Using data from UK databases and laboratory surveil-
lance, the model estimated that 28,516 hospitalisations
and 7163 deaths were attributable to influenza respira-
tory disease in a mean season, although there was con-
siderable between-season variability. Over the 13 seasons
of the study the long term trend appeared to be one of
decline, which is consistent with other UK estimates, in-
cluding estimates of general practitioner consultations
for influenza [4, 6]. The decline was most apparent for
influenza A. The reasons for this decline are not clear,
but could include the effects of repeated annual vac-
cination and decreasing virulence of circulating virus
strains. However, declines in influenza mortality during
this period have not been observed in other countries,
including Spain (1998–2005), Austria (2001–2009) and
the United States (1976–2007, and 1997–2009), attributed
in part to increasing longevity [15–18].
The overall burden of influenza B was substantial, with
hospitalisation and mortality rates approaching that of
influenza A in some seasons. Influenza B-attributable
hospitalisations were highest among 5–17 year olds,
which lends supports to recent changes to UK influenza
vaccine recommendations to extend vaccination to school
children aged 5–17 years, and suggest a potential benefit
for using quadrivalent influenza vaccines that contain both
influenza B lineages in this age group [5].
While estimated rates of hospitalisations and death
increased with age, there was a marked increase in eld-
erly 75+ years of age, who accounted for 36 % of all
Matias et al. BMC Public Health  (2016) 16:481 Page 7 of 9influenza-attributable respiratory hospitalisations. The
mean seasonal hospitalisation rate for influenza-attributable
respiratory disease in 75+ year olds was more than twice
that of 65–74 year olds. A modelling study of hospital ad-
missions in England attributable to influenza between 1989
and 2001 noted that 75+ year olds accounted for 52 % of
the total and 69 % of excess bed days occupancy [19]. Our
findings equally emphasise the impact of influenza in this
age group and the burden placed on health services. Of all
influenza-associated deaths, we estimated that 74 % oc-
curred in the 75+ year age group, although only 50 % of
influenza-attributable respiratory deaths (broadly defined)
in 75+ year olds occurred in hospital.
Differences in the way persons of differing ages use
primary care, hospital care and welfare accommodation
may bear on the interpretation of these findings. In
addition, many deaths from influenza occur in persons
who have not consulted a doctor, suggesting rapid death
early on in the illness [20]. It is possible that some of
these out-of-hospital deaths may be preventable, either
through more effective vaccines for the elderly, by redu-
cing exposure to influenza, by extending target age
groups for vaccination to increase herd immunity, or by
earlier access to anti-viral medication. Vaccination of
children up to 17 years of age may induce herd effects,
but it is not yet clear whether these effects will result in
benefits for the elderly who may have little contact with
young children. Increased use of post-exposure prophy-
laxis with anti-viral therapies in elderly persons may re-
duce hospitalisation and deaths in the elderly.
Several recent studies have used modelling approaches
and databases that are similar to the present study
[10, 21, 22]. Hardelid et al. [21], modelled all-cause
mortality and found an average of approximately 12,000
influenza-attributable deaths per season for the period
1999–2010, with 79 % of these deaths occurring in 75+
years old. This is close to our estimate of about 13,000
influenza-attributable cardiorespiratory deaths over our
study period. However, Pitman et al. [10] estimated a bur-
den of up to approximately 24,000 influenza-attributable
deaths per season during the earlier period 1990–2000.
Regarding the burden of hospitalisations, Cromer et al.
[22], studied the seasons 2000/01 to 2007/08 using a nar-
rower “acute respiratory illness” outcome definition and
estimated that approximately 34 hospitalisations per
100,000 population occurred per season, while we esti-
mated 49 respiratory hospitalisations and 43 cardiorespi-
ratory hospitalisations per 100,000 population. Pitman
et al. [10] found 59 cardiorespiratory hospitalisations per
100,000 population during an earlier period. Taking into
consideration the differences in modelling approaches,
outcome definitions and periods studied, these estimates
are in reasonable agreement with one another and consist-
ent with a long-term decline in the influenza burden [6].The comparability with other estimates also supports the
external validity of our model.
Influenza vaccination policy in the UK during the
study period recommended immunisation of individuals
from the age of 6 months with risk co-morbidities [12].
Our estimates show increased influenza-associated hos-
pitalisation and death in adults with comorbid condi-
tions, but the relative impact of comorbid conditions
was lower in the elderly than in younger adults, empha-
sising the importance of comorbid conditions in all age
groups except children. There was no apparent increase
when these comorbidity factors were present in children,
in whom asthma is numerically the most important risk
condition (data not shown).
A strength of our study is the use of the novel out-
come category ‘respiratory disease (broadly defined)’
which improved the outcome sensitivity and estimated
the burden of influenza-attributable disease for all age
groups consistently across the HES and ONS settings,
while retaining sufficient specificity. Estimates using the
respiratory disease (broadly defined) category compared
well to respiratory or cardiorespiratory definitions for
influenza-attributable hospitalisations. Respiratory disease
(broadly defined) hospitalization estimates were somewhat
larger than those for respiratory disease alone, indicating
that the new definition was, as intended, more sensi-
tive. However, influenza contributed more to excess
cardiorespiratory deaths in older adults than to hospitali-
zations, with the result that the cardiorespiratory mortality
estimate was higher. Other strengths include the long
study period which covered 13 seasons, and the use of age
stratification which allowed detailed estimation of the age-
specific burden. Tri-mean smoothing of outcome and
pathogen series reduced short-term effects such as na-
tional holidays and extreme weather conditions on viral
testing and hospitalisations. We assumed that weekly oc-
currences of outcomes were determined by the circulation
of influenza, RSV, and other causes which follow seasonal
trends, that we estimated using a combination of sine and
cosine terms. The inclusion of both cyclical terms (sine
and cosine functions) controlled for confounders for
which data are not available.
Potential limitations of our study are those related to
the modelling design, which assumes firstly that the
pathogen of interest is responsible for the outcomes
under consideration, that hospital admission thresholds
are similar nationally, and that consistency and uni-
formity in the quality of coding practices exists nation-
ally. However, because we used a control outcome
(hospitalisation for accidents) to detect confounding
[23], the expected absence of attributions for the negative
control provides support for the modelling methodology
employed. We did not have access to age-stratified
virology data and had to assume that patterns of
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child populations. Finally, we extrapolated data from
England, which makes up approximately 84 % of the
total UK population, to the whole of the UK. While
there are reasonable grounds for this approach [14], ex-
trapolation may have resulted in over- or underestima-
tion of the disease burden.
Conclusions
Detailed, age-specific estimates of the total burden of
influenza, including the burden in populations at
higher risk for influenza complications, can contribute
to cost-benefit analyses and inform decisions on vac-
cination and public health policy. Our results point to
a substantial but highly variable seasonal influenza
burden in all age groups, but particularly in those aged
75+ years. The high hospital admission mortality rate
and the smaller relative proportion of overall influenza
deaths happening in hospital in this age group indicates
that a substantial portion of influenza-related deaths occur
outside hospital, and so are not recorded as inpatients.
The development of effective influenza prevention strat-
egies in this age group is vital, as it puts major pressures
on hospital services because of the increased duration of
hospital admissions and difficulties surrounding discharge
[19]. Influenza vaccination of all age groups to increase
herd immunity and use of post-exposure prophylaxis
with anti-viral medications in the elderly could poten-
tially reduce hospitalisation and deaths due to influ-
enza, particularly in the 75+ year population.
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